Franklin Resources Inc. reduced its stake in BioNTech SE (NASDAQ:BNTX - Free Report) by 59.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,384 shares of the company's stock after selling 4,996 shares during the period. Franklin Resources Inc.'s holdings in BioNTech were worth $410,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. Planning Capital Management Corp lifted its position in shares of BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company's stock worth $54,000 after purchasing an additional 450 shares during the period. Blue Trust Inc. grew its position in BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company's stock worth $55,000 after purchasing an additional 388 shares during the last quarter. GAMMA Investing LLC increased its position in shares of BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company's stock valued at $74,000 after acquiring an additional 111 shares during the period. Daiwa Securities Group Inc. raised its stake in shares of BioNTech by 430.3% in the second quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company's stock worth $155,000 after purchasing an additional 1,562 shares during the last quarter. Finally, Caprock Group LLC purchased a new position in shares of BioNTech during the 2nd quarter valued at about $206,000. 15.52% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ BNTX opened at $113.95 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. BioNTech SE has a 1 year low of $76.53 and a 1 year high of $131.49. The company has a market capitalization of $27.32 billion, a price-to-earnings ratio of -54.26 and a beta of 0.22. The business has a 50-day moving average of $113.03 and a two-hundred day moving average of $101.51.
BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts' consensus estimates of ($1.26) by $2.07. The firm had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. BioNTech's quarterly revenue was up 38.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.73 earnings per share. On average, analysts forecast that BioNTech SE will post -3.72 earnings per share for the current fiscal year.
Several analysts recently commented on BNTX shares. Deutsche Bank Aktiengesellschaft raised their price target on shares of BioNTech from $95.00 to $150.00 and gave the company a "buy" rating in a research report on Thursday, September 19th. Evercore ISI raised BioNTech from an "in-line" rating to an "outperform" rating and increased their price target for the company from $110.00 to $125.00 in a report on Tuesday, November 19th. TD Cowen decreased their target price on shares of BioNTech from $132.00 to $122.00 and set a "hold" rating on the stock in a report on Tuesday, November 5th. Morgan Stanley raised BioNTech from an "equal weight" rating to an "overweight" rating and upped their price target for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. Finally, HSBC upped their price objective on shares of BioNTech from $97.00 to $136.00 and gave the stock a "buy" rating in a report on Monday, October 7th. Four analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, BioNTech currently has an average rating of "Moderate Buy" and a consensus target price of $140.76.
Read Our Latest Stock Report on BioNTech
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.